Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 20/20 | 0.63 |
| ▸ | TACR2 | P21452 | 2/20 | 0.55 |
| ▸ | TACR3 | P29371 | 2/20 | 0.55 |
| ▸ | CCR5 | P51681 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22901986 | 1.00 | TACR1 (0.63) | TACR1TACR2TACR3CCR5 | |
| Hydrochloric Acid SCHEMBL8840357 | 0.99 | TACR1 (0.62) | TACR1TACR2TACR3CCR5 | |
| SCHEMBL7765750 | 0.92 | CCR5 (0.55) | TACR1TACR2TACR3CCR5 | |
| Hydrochloric Acid SCHEMBL8483405 | 0.90 | CCR5 (0.54) | TACR1TACR2TACR3CCR5 | |
| Hydrochloric Acid SCHEMBL8840258 | 0.90 | CCR5 (0.54) | TACR1TACR2TACR3CCR5 | |
| SCHEMBL4631735 | 0.86 | TACR1 (0.47) | TACR1TACR2TACR3CCR5 | |
| SCHEMBL19440990 | 0.85 | TACR1 (0.50) | TACR1TACR2TACR3CCR5 | |
| SCHEMBL8991925 | 0.85 | TACR1 (0.50) | TACR1TACR2TACR3CCR5 | |
| Hydrochloric Acid SCHEMBL7749206 | 0.85 | TACR1 (0.46) | TACR1TACR2TACR3CCR5 | |
| Hydrochloric Acid SCHEMBL7749200 | 0.85 | TACR1 (0.46) | TACR1TACR2TACR3CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180021327-A1 | TREATMENT OF CORNEAL NEOVASCULARIZATION | IRBM SCIENCE PARK S.P.A. (IT) | 2018-01-25 | — | — | US | disclosed |
| US-9782397-B2 | Treatment of corneal neovascularization | IRBM SCIENCE PARK S.P.A. (IT) | 2017-10-10 | — | — | US | disclosed |
| EP-0723959-A1 | Heterocyclic compounds as tachykinin receptor antagonists, process for their preparation and pharmaceuticals containing them | SANOFI (FR) | 1996-07-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180021327-A1 | TREATMENT OF CORNEAL NEOVASCULARIZATION | KDR, BAK1, FLT1 | TACR1 119/4885TACR2 52/4885TACR3 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.